Journal
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Volume 41, Issue 5, Pages 429-435Publisher
OXFORD UNIV PRESS
DOI: 10.1093/abbs/gmp027
Keywords
single nucleotide polymorphism; gene-chip; XPA; XPG; nucleotide excision repair; non-small cell lung cancer; chemotherapy
Categories
Funding
- Jiangsu Province Nature Fund [BK2005203]
- Medicine Science Technology Research 'Eleventh Five-Year' Program of PLA [06MA111]
- Focal Project of Nanjing Medicine Technology Development [ZKX05030]
Ask authors/readers for more resources
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A -> G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available